Dawn Bell

Executive Profile

Dr. Dawn Bell has been starting and scaling life-science businesses from academic spinouts to Top 5 Pharma for over 20 years.  She is a founder, operator, and board director with diverse experience across drug development and commercialization.  Her career spans buy and sell-side BD&L, portfolio strategy, R&D, medical affairs, and market access in both private and public companies (NYSE: NVS; NASDAQ: MDCO). She is CEO of Antlia Biosciences, a pre-clinical stage company developing long-acting peptides for patients with severe cardiovascular diseases, where she raised a $12M seed backed by Curie Bio and F*Prime.  She is also co-founder and board director of Myracle Therapeutics, an academic spinout targeting adipocytes in obesity and metabolic health.  She serves on the boards STRM Bio and New York BIO.

 

Career Highlights

• Delivered Entresto ($3.5B) approval 18 months ahead of schedule as global GM. Secured Break-Through and Fast-Track status at the FDA.

• Led development and launch of 12+ medicines across 8 therapeutic areas. Built the team that launched the 1st two gene therapies approved in Canada.

• Led sell-side BD&L process resulting in out-licensing of a novel biologic for rare hematologic disease; Buy-side BD&L leader at Novartis with full visibility into BD&L and M&A decision-making and governance processes.

• Founding CEO of two academic spin-outs (Emory University and University of Colorado)

• Early commercial leader at The Medicines Company (NASDAQ:  MDCO) contributing to market cap growth from $400M to >$2B over 3 years.

​

Awards and Honors

University of Florida College of Pharmacy Alumnus of the Year, 2022.

Awarded for extraordinary accomplishments and exceptional achievements which have brought pride, honor, and recognition to the College.

 

Creative Destruction Lab, Mentor of the Year Toronto, 2018

Selected by founder-led, science-based start-up ventures out of 100+ mentors.